To understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending $57 billion more per year on research and development than the value of the products it has been launching. That’s a problem.
Eli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.
Marvin Pember, 58, is taking a new job near Philadelphia as the president of the acute care division of Universal Health Services Inc., a publicly traded company with 22 acute hospitals and numerous behavioral health centers spread from coast to coast.
A Hamilton County jury sided with Joseph Radcliff in his lengthy legal battle with the insurer following a 2006 hailstorm that caused severe damage in central Indiana. State Farm accused Radcliff of fraud.
Lilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s disease, up from seven in 2005, the Indianapolis-based company said Thursday.
Indianapolis-based Eli Lilly and Co. raised its spending 8 percent from the $2.3 million that it spent in the first quarter of last year. The drugmaker also spent 70 percent more than the $1.5 million recorded in the final quarter of 2010, according to lobbying reports filed with the House of Representatives.
WellPoint Inc., the nation's largest health insurer based on membership, spent about $1.5 million lobbying the federal government in the first quarter, as the health care overhaul debuted a new restriction that concerned managed care companies.
Indianapolis-based Arcadia Resources Inc.’s auditor issued a “going-concern” warning Tuesday in the once-promising company’s annual report.
Baldwin & Lyons Inc. expects to lose another $10 million due to worldwide catastrophes that occurred in the first half of the year, the Indianapolis-based property and casualty insurer reported Tuesday.
Indiana's attorney general has appealed a judge's decision blocking part of new abortion law that took away some of the public funding for Planned Parenthood of Indiana.
As part of its agreement to add Westview Hospital to its system, Community Health Network will assume $10 million in debt, spend $7.5 million on upgrades, and help open an outpatient center in Speedway, the two hospitals announced Tuesday morning.
Indianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act like two medicines in one. Lilly plans to add more scientists to back the effort.
Jim Alender has been CEO of Howard Regional Health System in Kokomo since 1997. He recently negotiated a letter of intent to merge the hospital with Indianapolis-based Indiana University Health. He spoke about the major factors that led to that decision, and the benefits he hopes to come from it. The deal, which still requires approval from Howard County officials, could close before the end of this year.
Help with physician recruitment is a big factor pushing small-city hospitals into the arms of Indianapolis’ four major hospital systems. So how do the big boys entice doctors to the small towns?
The U.S. Supreme Court has refused to revive a bid to press a $6.8 billion class-action suit against Eli Lilly and Co. over the marketing of Zyprexa, the company’s schizophrenia treatment.
Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
Planned Parenthood of Indiana expects to resume offering services to Medicaid patients following a judge's ruling that the state is not allowed to cut off the organization's public funding for general health services solely because it also provides abortions.
Eli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval in Europe, putting the drug on track to enter the region’s market this year.
Health insurer WellPoint Inc. has enlisted Google Maps for new websites that help patients think twice before they visit an emergency room for care that a less-expensive retail health clinic could handle.
